Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents-Reference-Cited by-同舟云学术

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor Agents

Published:2016-02 Issue:2 Volume:14 Page:242-250.e2
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Wils Pauline,Bouhnik Yoram,Michetti Pierre,Flourie Bernard,Brixi Hedia,Bourrier Anne,Allez Matthieu,Duclos Bernard,Grimaud Jean-Charles,Buisson Anthony,Amiot Aurélien,Fumery Mathurin,Roblin Xavier,Peyrin-Biroulet Laurent,Filippi Jérôme,Bouguen Guillaume,Abitbol Vered,Coffin Benoit,Simon Marion,Laharie David,Pariente Benjamin

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference26 articles.

1. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis;Pearson;Ann Intern Med,1995

2. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators;Feagan;N Engl J Med,2000

3. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

4. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial;Colombel;Gastroenterology,2007

5. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health;Peyrin-Biroulet;Inflamm Bowel Dis,2010

Cited by 163 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU;Digestive and Liver Disease;2024-06

2. Clinical effectiveness and safety of ustekinumab in youth with refractory inflammatory bowel disease: A retrospective cohort study;Saudi Journal of Gastroenterology;2024-04-10

3. Safety and Effectiveness of Ustekinumab for Crohn’s Disease With Perianal Manifestations: Ad hoc Analysis Data From 1-Year Post-Marketing Surveillance Study in Japan;Crohn's & Colitis 360;2024-04-01

4. Defining predictors of responsiveness to advanced therapies in Crohn’s disease and ulcerative colitis: protocol for the IBD-RESPONSE and nested CD-metaRESPONSE prospective, multicentre, observational cohort study in precision medicine;BMJ Open;2024-04

5. The role of goblet cells in Crohn’ s disease;Cell & Bioscience;2024-04-01